verapamil has been researched along with Pulmonary Disease, Chronic Obstructive in 6 studies
Verapamil: A calcium channel blocker that is a class IV anti-arrhythmia agent.
verapamil : A racemate comprising equimolar amounts of dexverapamil and (S)-verapamil. An L-type calcium channel blocker of the phenylalkylamine class, it is used (particularly as the hydrochloride salt) in the treatment of hypertension, angina pectoris and cardiac arrhythmia, and as a preventive medication for migraine.
2-(3,4-dimethoxyphenyl)-5-{[2-(3,4-dimethoxyphenyl)ethyl](methyl)amino}-2-(propan-2-yl)pentanenitrile : A tertiary amino compound that is 3,4-dimethoxyphenylethylamine in which the hydrogens attached to the nitrogen are replaced by a methyl group and a 4-cyano-4-(3,4-dimethoxyphenyl)-5-methylhexyl group.
Pulmonary Disease, Chronic Obstructive: A disease of chronic diffuse irreversible airflow obstruction. Subcategories of COPD include CHRONIC BRONCHITIS and PULMONARY EMPHYSEMA.
| Excerpt | Relevance | Reference |
|---|---|---|
| "Chronic obstructive pulmonary disease (COPD) is associated with many health complications, including pulmonary hypertension (PH)." | 7.11 | Clinical evaluation of nebulized verapamil in out-patients with pulmonary hypertension secondary to chronic obstructive pulmonary disease. ( Behzadnia, N; Esmaeili, A; Fahimi, F; Forough, AS; Mostofi, SS; Parto, O; Pourdowlat, G, 2022) |
| "The beneficial impact of inhaled verapamil on the diminishing of dyspnea score along with its bronchodilatory effect would make this selective calcium blocker agent a therapeutic option in COPD." | 5.34 | Therapeutic effects of nebulized verapamil on chronic obstructive pulmonary disease: A randomized and double-blind clinical trial. ( Abtahi, H; Amini, S; Bozorgmehr, R; Edalatifard, M; Ghorbani, F; Pourdowlat, G; Rahimi, B; Safavi, E, 2020) |
| "Chronic obstructive pulmonary disease (COPD) is associated with many health complications, including pulmonary hypertension (PH)." | 3.11 | Clinical evaluation of nebulized verapamil in out-patients with pulmonary hypertension secondary to chronic obstructive pulmonary disease. ( Behzadnia, N; Esmaeili, A; Fahimi, F; Forough, AS; Mostofi, SS; Parto, O; Pourdowlat, G, 2022) |
| "Verapamil did not increase systemic exposure to VI following administration of the UMEC/VI combination." | 2.78 | Effect of verapamil on systemic exposure and safety of umeclidinium and vilanterol: a randomized and open-label study. ( Crater, G; Hughes, S; Kelleher, D; Mehta, R; Preece, A, 2013) |
| "The incidence of COPD patients is gradually increasing, especially in patients over 45 years old." | 1.72 | Bioinformatics Approach Predicts Candidate Targets for SARS-CoV-2 Infections to COPD Patients. ( Cai, X; Che, L; Chen, G; Liu, S; Xia, T; Xie, Z; Zhang, W, 2022) |
| "Within the COPD GOLD II stage group, there appears to be no statistically significant difference in the number of exacerbations between the patients taking verapamil and digoxin (n = 24) and the patients taking BBs alone (n = 15), although, in patients taking BBs alone, there appears to be a trend towards a decrease in the exacerbations compared to the number of exacerbations in patients taking verapamil and digoxin (p = 0." | 1.51 | Beta-blocker Use in Moderate and Severe Chronic Obstructive Pulmonary Disease. ( Bedak, O; Begic, E; Bradaric, H; Custovic, F; Durak-Nalbantic, A; Hodzic, E; Mujakovic, A; Prnjavorac, B; Zvizdic, F, 2019) |
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 0 (0.00) | 29.6817 |
| 2010's | 3 (50.00) | 24.3611 |
| 2020's | 3 (50.00) | 2.80 |
| Authors | Studies |
|---|---|
| Che, L | 1 |
| Chen, G | 1 |
| Cai, X | 1 |
| Xie, Z | 1 |
| Xia, T | 1 |
| Zhang, W | 1 |
| Liu, S | 1 |
| Fahimi, F | 1 |
| Pourdowlat, G | 2 |
| Behzadnia, N | 1 |
| Mostofi, SS | 1 |
| Forough, AS | 1 |
| Parto, O | 1 |
| Esmaeili, A | 1 |
| Zvizdic, F | 1 |
| Begic, E | 1 |
| Mujakovic, A | 1 |
| Hodzic, E | 1 |
| Prnjavorac, B | 1 |
| Bedak, O | 1 |
| Custovic, F | 1 |
| Bradaric, H | 1 |
| Durak-Nalbantic, A | 1 |
| Bozorgmehr, R | 1 |
| Edalatifard, M | 1 |
| Safavi, E | 1 |
| Rahimi, B | 1 |
| Ghorbani, F | 1 |
| Abtahi, H | 1 |
| Amini, S | 1 |
| Mehta, R | 1 |
| Kelleher, D | 1 |
| Preece, A | 1 |
| Hughes, S | 1 |
| Crater, G | 1 |
| Sweeney, D | 1 |
| Hollins, F | 1 |
| Gomez, E | 1 |
| Saunders, R | 1 |
| Challiss, RA | 1 |
| Brightling, CE | 1 |
| Trial | Phase | Enrollment | Study Type | Start Date | Status | ||
|---|---|---|---|---|---|---|---|
| A Single-Centre, Randomised, Open-label Study to Evaluate the Effects of Steady-State Verapamil, a Moderate P-Glycoprotein and CYP3A4 Inhibitor, on the Pharmacokinetics of GSK573719 and GSK573719 in Combination With GW642444[NCT01128634] | Phase 1 | 32 participants (Actual) | Interventional | 2010-03-04 | Completed | ||
| [information is prepared from clinicaltrials.gov, extracted Sep-2024] | |||||||
3 trials available for verapamil and Pulmonary Disease, Chronic Obstructive
| Article | Year |
|---|---|
Clinical evaluation of nebulized verapamil in out-patients with pulmonary hypertension secondary to chronic obstructive pulmonary disease.
Topics: Administration, Inhalation; Double-Blind Method; Forced Expiratory Volume; Humans; Hypertension, Pul | 2022 |
Therapeutic effects of nebulized verapamil on chronic obstructive pulmonary disease: A randomized and double-blind clinical trial.
Topics: Administration, Inhalation; Aged; Calcium Channel Blockers; Double-Blind Method; Dyspnea; Female; Fo | 2020 |
Effect of verapamil on systemic exposure and safety of umeclidinium and vilanterol: a randomized and open-label study.
Topics: Administration, Oral; Adolescent; Adrenergic beta-2 Receptor Agonists; Adult; Aged; Benzyl Alcohols; | 2013 |
3 other studies available for verapamil and Pulmonary Disease, Chronic Obstructive
| Article | Year |
|---|---|
Bioinformatics Approach Predicts Candidate Targets for SARS-CoV-2 Infections to COPD Patients.
Topics: Artesunate; Computational Biology; COVID-19; Gene Expression Profiling; Gene Regulatory Networks; Hu | 2022 |
Beta-blocker Use in Moderate and Severe Chronic Obstructive Pulmonary Disease.
Topics: Adrenergic beta-Antagonists; Anti-Arrhythmia Agents; Arrhythmias, Cardiac; Bisoprolol; Case-Control | 2019 |
[Ca2+]i oscillations in ASM: relationship with persistent airflow obstruction in asthma.
Topics: Adult; Aged; Asthma; Biopsy; Caffeine; Calcium Signaling; Case-Control Studies; Female; Forced Expir | 2014 |